<DOC>
	<DOC>NCT02305758</DOC>
	<brief_summary>This study seeks to evaluate the efficacy and tolerability of veliparib in combination with FOLFIRI +/- bevacizumab in previously untreated, metastatic adenocarcinoma of the colon or rectum. FOLFIRI is a chemotherapy regimen of fluorouracil, leucovorin and irinotecan. This is a blinded study such that the Investigator and Subject will be blinded but AbbVie will be unblinded.</brief_summary>
	<brief_title>Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum At least 1 unresectable lesion on a CT (Computerized Tomography) scan that is measurable as defined by RECIST, Version 1.1 ECOG (Eastern Cooperative Oncology Group) performance score of 0 or 1 Adequate hematologic, renal and hepatic function Prior anticancer treatment for metastatic colorectal cancer Prior exposure to PARP (poly ADPribose polymerase) inhibitors The last course of adjuvant or neoadjuvant chemotherapy must have ended &gt; 12 months prior to colorectal cancer recurrence Any clinically significant and uncontrolled major medical condition Participant is pregnant or lactating Any medical condition, which in the opinion of the study Investigator, places the participant at an unacceptably high risk for toxicities For those receiving bevacizumab, standard medical exclusionary conditions apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>fluorouracil</keyword>
	<keyword>irinotecan</keyword>
	<keyword>colon cancer</keyword>
	<keyword>veliparib</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>previously untreated</keyword>
	<keyword>ABT-888</keyword>
	<keyword>first line</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>5-FU</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>leucovorin</keyword>
</DOC>